Predictable hematological markers associated with cognitive decline in valid rodent models of cognitive impairment

References

• Akbarzadeh A, Norouzian D, Mehrabi MR, Jamshidi S, Farhangi A, Verdi AA, Mofidian SMA, Rad BL. 2007. Induction of diabetes by Streptozotocin in rats. Indian J Clin Biochem. 22(2):60–64.
   PubMedGoogle Scholar
• Alexopoulos CG, Pournaras S, Vaslamatzis M, Avgerinos A, Raptis S. 1992. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol. 30(5):412–416.
   PubMed Web of Science ®Google Scholar
• Alyamkina EA, Nikolin VP, Popova NA, Dolgova EV, Proskurina AS, Orishchenko KE, Efremov YR, Chernykh ER, Ostanin AA, Sidorov SV, et al. 2010. A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation. Genet Vaccines Ther. 8(1):7.
   PubMedGoogle Scholar
• Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP. 2011. Either called “Chemobrain” or “Chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage. 41(1):126–139.
   PubMed Web of Science ®Google Scholar
• Asher A, Myers JS. 2015. The effect of cancer treatment on cognitive function. Clin Adv Hematol Oncol. 13(7):441–450.
   PubMed Web of Science ®Google Scholar
• Banks WA, Farr SA, Salameh TS, Niehoff ML, Rhea EM, Morley JE, Hanson AJ, Hansen KM, Craft S. 2018. Triglycerides cross the blood–brain barrier and induce central leptin and insulin receptor resistance. Int J Obes. 42(3):391–397.
   PubMed Web of Science ®Google Scholar
• Beckman KB, Ames BN. 1998. The free radical theory of aging matures. Physiol Rev 78(2):547–581.
   PubMed Web of Science ®Google Scholar
• Biessels GJ, van der Heide LP, Kamal A, Bleys RLA, Gispen WH. 2002. Ageing and diabetes: implications for brain function. Eur J Pharmacol. 441(1-2):1–14.
   PubMed Web of Science ®Google Scholar
• Burns M, Duff K. 2002. Cholesterol in Alzheimer’s disease and tauopathy. Ann N Y Acad Sci. 977(1):367–375.
   PubMedGoogle Scholar
• CDC 2011. Cognitive impairment: a call for action, Now! Atlanta, GA: CDC.
   Google Scholar
• Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D. 1998. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 50(1):164–168.
   PubMed Web of Science ®Google Scholar
• de Frias CM, Bunce D, Wahlin A, Adolfsson R, Sleegers K, Cruts M, Van Broeckhoven C, Nilsson L-G. 2007. Cholesterol and triglycerides moderate the effect of apolipoprotein E on memory functioning in older adults. J Gerontol B Psychol Sci Soc Sci. 62(2):P112–P118.
   PubMed Web of Science ®Google Scholar
• de Haan EH, Nys GM, Van Zandvoort MJ. 2006. Cognitive function following stroke and vascular cognitive impairment. Curr Opin Neurol. 19:559–564.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, El ReFaey H, Carlson EC. 2006. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. CDT. 7(11):1513–1529.
   Google Scholar
• Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DHS, Geist C, Breen EC, Irwin MR, Cole SW. 2013. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 30:S99–S108.
   PubMed Web of Science ®Google Scholar
• Gao S, Cheng Y, Jin Y, Unverzagt F, Su L, Yang L, Ma F, Hake A, Kettler C, Chen C, et al. 2014. The relationship between cholesterol and cognitive function is homocysteine-dependent. Clin Interv Aging. 9:1823–1829.
   PubMed Web of Science ®Google Scholar
• Gaspar JM, Baptista FI, Galvão J, Castilho ÁF, Cunha RA, Ambrósio AF. 2010. Diabetes differentially affects the content of exocytotic proteins in hippocampal and retinal nerve terminals. Neuroscience. 169(4):1589–1600.
   PubMed Web of Science ®Google Scholar
• Hoyer S. 1998. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm. 105(4):415.
   PubMed Web of Science ®Google Scholar
• Janelsins MC, Kesler SR, Ahles TA, Morrow GR. 2014. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 26(1):102–113.
   PubMed Web of Science ®Google Scholar
• Johansen PB. 1981. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol. 5(4):267–270.
   PubMed Web of Science ®Google Scholar
• Kim B, Feldman EL. 2015. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 47(3):e149–e149.
   PubMedGoogle Scholar
• Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR. 2001. Atherosclerosis Risk in Communities (ARIC) study investigators, cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 56(1):42–48.
   PubMed Web of Science ®Google Scholar
• Kodl CT, Seaquist ER. 2008. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 29(4):494–511.
   PubMed Web of Science ®Google Scholar
• Kumagai AK. 1999. Glucose transport in brain and retina: implications in the management and complications of diabetes. Diabetes Metab Res Rev. 15(4):261–273.
   PubMed Web of Science ®Google Scholar
• Mankovsky BN, Metzger BE, Molitch ME, Biller J. 1996. Cerebrovascular disorders in patients with diabetes mellitus. J Diabetes Complications. 10(4):228–242.
   PubMed Web of Science ®Google Scholar
• Mayo Clinic 2019. Chemo brain - Symptoms and causes - Mayo Clinic. [accessed 2019 June 26]. https://www.mayoclinic.org/diseases-conditions/chemo-brain/symptoms-causes/syc-20351060
   Google Scholar
• McCall AL. 2004. Cerebral glucose metabolism in diabetes mellitus. Eur J Pharmacol. 490(1–3):147–158.
   PubMed Web of Science ®Google Scholar
• Mostafavinia A, Amini A, Ghorishi SK, Pouriran R, Bayat M. 2016. The effects of dosage and the routes of administrations of streptozotocin and alloxan on induction rate of type1 diabetes mellitus and mortality rate in rats. Lab Anim Res. 32(3):160–165.
   PubMedGoogle Scholar
• Neergaard JS, Dragsbaek K, Christiansen C, Nielsen HB, Brix S, Karsdal MA, Henriksen K. 2017. Metabolic syndrome, insulin resistance, and cognitive dysfunction: does your metabolic profile affect your brain? Diabetes. 66(7):1957–1963.
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. 1999. Diabetes mellitus and the risk of dementia: the rotterdam study. Neurology. 53(9):1937–1942.
   PubMed Web of Science ®Google Scholar
• Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, Larkin M. 1988. Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J Diabet Complications. 2(4):210–213.
   PubMedGoogle Scholar
• Rösen P, Nawroth PP, King G, MöLler W, Tritschler H-J, Packer L. 2001. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 17(3):189–212.
   PubMed Web of Science ®Google Scholar
• Shao TN, Yin GZ, Yin XL, Wu JQ, Du XD, Zhu HL, Liu JH, Wang XQ, Xu DW, Tang WJ, et al. 2017. Elevated triglyceride levels are associated with cognitive impairments among patients with major depressive disorder. Compr Psychiatry. 75:103–109.
   PubMed Web of Science ®Google Scholar
• Shavali S, Ren J, Ebadi M. 2003. Insulin-like growth factor-1 protects human dopaminergic SH-SY5Y cells from salsolinol-induced toxicity. Neurosci Lett. 340(2):79–82.
   PubMed Web of Science ®Google Scholar
• Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, et al. 2012. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 122(4):1316–1338.
   PubMed Web of Science ®Google Scholar
• Tryon WW. 2014. Introduction. In: Tryon WW, editor. Cognitive neuroscience and psychotherapy: network principles for a unified theory. 1st ed. Academic Press. p. 5–66.
   Google Scholar
• van Vliet P. 2012. Cholesterol and late-life cognitive decline. J Alzheimers Dis. 30(s2):S147–S162.
   PubMedGoogle Scholar
• Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. 1994. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA. 91(11):4766–4770.
   PubMed Web of Science ®Google Scholar
• Vlassara H. 1997. Recent progress in advanced glycation end products and diabetic complications. Diabetes. 46(Supplement_2):S19–S25.
   PubMedGoogle Scholar
• Wefel JS, Kesler SR, Noll KR, Schagen SB. 2015. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults, CA. Cancer J Clin. 65(2):123–138.
   PubMed Web of Science ®Google Scholar
• Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR. 2009. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke. 40(10):3180–3185.
   PubMed Web of Science ®Google Scholar
• Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BEK, Liao D-P, Hubbard LD, Mosley TH, For t. A. 2002. Investigators, cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA. 288(1):67.
   PubMed Web of Science ®Google Scholar
• Wright CB, Festa JR, Paik MC, Schmiedigen A, Brown TR, Yoshita M, DeCarli C, Sacco R, Stern Y. 2008. White matter hyperintensities and subclinical infarction. Stroke. 39(3):800–805.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Whaley-Connell AT, Sowers JR, Ren J. 2018. Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. Pharmacol Ther. 191:1–22. Nov Epub 2018 Jun 22.
   PubMed Web of Science ®Google Scholar
• Zhao X, Han Q, Lv Y, Sun L, Gang X, Wang G. 2018. Biomarkers for cognitive decline in patients with diabetes mellitus: evidence from clinical studies. Oncotarget. 9(7):7710–7726.
   PubMedGoogle Scholar